Kate Hermans and Feng Tian
August 17, 2022 07:27 AM EDT
People
R&D

Squeezed by As­traZeneca/Dai­ichi Sankyo, biotech de­vel­op­ing HER2 ADC switch­es CEO, launch­es pipeline re­view

Amber Tong

When Am­brx Bio­phar­ma went pub­lic in the sum­mer of 2021 — join­ing in on the go-go times in biotech — ex­ecs cel­e­brat­ed it as the cul­mi­na­tion of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times